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Abstract
Recombinant viruses labelled with fluorescent proteins are useful tools in molecular virology with multiple applications
(e.g., studies on intracellular trafficking, protein localization, or gene activity). We generated by homologous recombination
three recombinant cytomegaloviruses carrying the enhanced yellow fluorescent protein (EYFP) fused with the viral proteins
IE-2, ppUL32 (pp150), and ppUL83 (pp65). In growth kinetics, the three viruses behaved all like wild type, even at low
multiplicity of infection (MOI). The expression of all three fusion proteins was detected, and their respective localizations
were the same as for the unmodified proteins in wild-type virus–infected cells. We established the in vivo measurement of
fluorescence intensity and used the recombinant viruses to measure inhibition of viral replication by neutralizing antibodies
or antiviral substances. The use of these viruses in a pilot screen based on fluorescence intensity and high-content analysis
identified cellular kinase inhibitors that block viral replication. In summary, these viruses with individually EYFP-tagged
proteins will be useful to study antiviral substances and the dynamics of viral infection in cell culture.
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Introduction
The human cytomegalovirus (HCMV) is a herpesvirus belong-
ing to the Betaherpesvirinae subfamily. With a genome size of
approximately 235 kbp it contains one of the largest genomes
among viruses. HCMV is known to have a narrow host range
infecting only humans, where 40–90% of the global human
population become seropositive after primary infection. Postnatal
primary infection is usually asymptomatic in immune competent
hosts and is followed by a lifelong persistence. In individuals with
an immature or compromised immune system HCMV can cause
considerable morbidity and mortality [1,2].
The replication cycle of HCMV in the host can be divided into
three different phases, the IE-phase, where mainly genes with
regulatory functions are expressed, the early-phase for the
expression of enzymatic proteins and the late-phase for expression
of the structural components [3,4]. A prominent gene product of
the immediate-early phase is the IE2 protein, which is essential for
viral replication and functions as activating and repressing
transcription factor [5–8]. The expression of the structural
proteins ppUL83 (pp65) and ppUL32 (pp150) starts during the
early and late phase, respectively. The lower matrix protein
ppUL83 is a non-essential protein for replication in fibroblasts but
important for replication in macrophages [9,10]. It first accumu-
lates in the nucleus of infected cells but is translocated to the
cytoplasm in the late phase in a process which depends on cyclin-
dependent kinases and the Crm1 exporter [11]. As a component of
the tegument, ppUL83 is located inside the virion but is also the
main component of dense bodies [12]. About 20% of the protein
components of viral particles comprise ppUL83 which is the main
acceptor for phosphate during viral replication [4]. The true late
protein ppUL32 (pp150) is an essential protein [4,13,14]. This
basic phosphoprotein is also a major component of the tegument
and is able to bind to the viral capsid [12,15].
Recombinant fluorescent viruses have been generated for other
viruses to investigate the movement of viral particles inside the
infected cell [16–21]. For HCMV several studies have been
published showing ectopic expression of the green fluorescent
protein [22–24]. In addition, fusions of EGFP with the IE2 protein
[25] and the structural protein ppUL32 [26] have been reported.
In the present study we used a variant of Aequorea victoria green
fluorescent protein (GFP) for the labelling of viral proteins. The
enhanced yellow fluorescent protein (EYFP) is a mutant of the
avEGFP with an emission maximum of 530 nm instead of 509 nm
for the EGFP [27]. Compared to EGFP the EYFP has a higher
absorption and quantum yield [28]. This shift in emission causes
an improved intensity of the EYFP compared to EGFP, and the
relative auto-fluorescence of the cells is strongly reduced. The
reduction of the auto-fluorescence is very important for the use of
these fluorescent viruses. In addition, fusions with EYFP have been
used in conjunction with ECFP-fusions for FRET measurements
to monitor protein-protein interactions in viable intact cells [29].
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9174In this study we generated by recombineering (genetic
engineering by recombination [30,31]) modified HCMV viruses
with EYFP fused to the immediate-early protein IE2, the early-late
protein ppUL83 and the true late protein ppUL32. First, we
characterized expression and localization of the modified proteins
in comparison with the wild type proteins. Having done this, we
evaluated our fluorescent viruses in a relevant application, namely
the screening of antiviral compounds in intact cells. We show here,
that the recombinant viruses can be used to quantify the inhibition
of viral replication by neutralizing antibodies or to screen for
antiviral substances by measuring the fluorescence intensity in
intact cells.
Results
Generation of EYFP-Expressing HCMV
To generate virus variants encoding fusions of viral proteins with
EYFP we first generated a plasmid template suitable for
recombineering. Plasmid pSL-FRT-EYFP contained the EYFP
gene adjacent to a kanamycin resistance gene, which was flanked by
FRT sites to allow subsequent removal (Fig. 1A). We chose to
generate fusions with an immediate-early (IE2), a delayed-early
(ppUL83) and a true late (ppUL32) gene in the context of strain
TB40E-BAC4 (thereafter called TB4). The EYFP-kanamycin
region was amplified with primers containing sequences homolo-
gous tothe respective insertion sites (Fig.1B). Primers were designed
to remove the stop codon of the viral gene. In addition, a GPGP-
linker peptide was encoded by the fusion primer between the last
codon of the viral gene and the first EYFP codon. This peptide
should ensure conformational uncoupling between the viral protein
and EYFP. After successful recombinationthe kanamycin resistance
cassette was removed by FLP-based recombination leaving the
fused EYFP gene and one FRT-site behind.
The recombinant BAC genomes were analyzed by restriction
digest and southern blot analysis, using probes of the regions
flanking the insertion sites. As shown in Fig. 2A, D, G no
unexpected alterations of the genomes were observed. Specific
alterations of certain restriction fragments corresponded to
fragments altered by insertion of EYFP, as shown in Fig. 2.
Specifically, insertionof the EYFP-kanamycin cassette increased the
fragmentsby2 kbandthiswassubsequentlyreducedby1.1 kbafter
removal of kanamycin. In the case of TB4-IE2-EYFP, the flanking
probes (Fig. 2B) detected a single fragment of 4 (lane 3), 6 (lane 1)
and 5 kb (lane 2), respectively, corresponding to wild type or
recombinant viruses with or without kanamycin, respectively.
Accordingly, the 6 and 5 kb fragments were also detected with
the EYFP-specific probe, as expected (Fig. 2C). In the case of TB4-
UL83-EYFP, the flanking probes (Fig. 2E) detected two bands of 1
and 10 kb in the wild type virus, were the 10 kb fragment was
increased to 12 or 11 kb in the recombinant genomes with or
Figure 1. Construction of recombinant HCMV TB40E-EYFP. (A) Map of the pSL-FRT-EYFP plasmid. Open reading frames and FRT-sites are
indicated. Primer binding sites used for amplification were gfpBAC-primer and gene-primer. (B) Scheme of ET-cloning. The EYFP/Kan-cassette was
amplified by PCR and used for recET-based recombination to fuse EYFP to the C-terminus of the gene of interest. This resulted in a BAC still
containing the kanamycin resistance gene (kan BAC). By transformation of a plasmid encoding the FLP recombinase the kanamycin resistance was
removed, leaving a BAC with gene-EYFP fusion and a FRT-site (gene-YFP BAC).
doi:10.1371/journal.pone.0009174.g001
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(Fig. 2F) detected only the 12 and 11 kb fragments in the
recombinant genomes. Finally, the flanking probes for UL32
(Fig. 2H) detected two signals of 0.8 and .20 kb. Here the size of
the small fragment increased to 2.5 or 1.4 kb in the recombinant
viruses with or without kanamycin; these fragments also contained
EYFP (Fig. 2I). In summary, we successfully generated fusions of
EYFP to IE2, UL83 and UL32, respectively, in the context of the
genome of HCMV strain TB40E.
No Growth Defect of Variant Viruses
The recombinant BACs were reconstituted in HFF. To analyze
if the fusion of EYFP to the selected viral proteins affected growth
in cell culture, we infected human fibroblasts with wild type or
modified viruses at an MOI of 1 and the virus yield was
determined over a range of 10 days post infection. As shown in
Fig. 3A, no significant difference in growth properties was
observed between wild type and any of the fluorescent viruses.
Since minor growth defects become more apparent upon infection
at low MOI [32–34], we determined additional one-step growth
curves at MOI 0.1 (Fig. 3B) and 0.01 (Fig. 3C). The modified
viruses grew like wild type TB4-wt even at the low MOI of 0.01.
Since no significant growth defect was observed, these viruses
should be useful tools for either analyzing the normal viral life
cycle or the inhibition of viral replication by fluorescence
microscopy or fluorescence measurement.
The Fusion Products of Viral Proteins with EYFP Can Be
Detected by Western Blot Analysis
Next, we were interested whether the fusion proteins were
correctly synthesized and localized. First, we performed immuno-
blot analyses of cells infected with the different recombinant viruses.
HFF cells were infected with an MOI of 1 and harvested at 24 hpi
(IE2-EYFP) or 72 hpi (UL83-EYFP and UL32-EYFP). Fusion
proteins were detected using specific antibodies directed against the
respective viral protein or GFP. The IE2-EYFP fusion proteincould
be readily detected as a band of about 115 kDa, both by an IE1/2
specific serum (Fig. 4A) and a GFP-specific serum (Fig. 4B). An
additional band at 72 kDa represented the IE1 protein, which was
not modified in the TB4-IE2-EYFP virus. In cells infected with
TB4-UL83-EYFP two bands of 65 and 95 kDa were detected by a
monoclonal antibody directed against ppUL83 (pp65) (Fig. 4C).
The 95 kDa band corresponded to the ppUL83-EYFP fusion
protein, as demonstrated by staining with the anti-GFP serum
(Fig. 4D), whereas the 65 kDa band represented either a product of
incomplete synthesis or post-translational processing. However, no
free EYFP (expected size 28 kDa) was detected (Fig. 4D), indicating
incomplete synthesis. A band of the expected size of 180 kDa was
also observed in cells infected with TB4-UL32-EYFP, both with
anti-ppUL32 monoclonal antibody (Fig. 4E) and anti-GFP serum
(Fig. 4F). Two bands of 100 and 75 kDa represent unspecific signals
of the anti-ppUL32 monoclonal antibody.
Since ppUL83 (pp65) and ppUL32 (pp150) represent major
components of the virus particle we analyzed concentrated viral
particles for the presence of EYFP-fusion proteins in the respective
virus variants. Viral particles were standardized for equal amount of
major capsid protein (MCP), as shown in Fig. 4G. By immunoblot
using an anti-GFP serum both ppUL83-EYFP and ppUL32-EYFP
could be readily detected (Fig. 4G). No GFP signals were observed
for particles of the wild type virus and the TB4-IE2-EYFP variant.
Since IE2 is not incorporated into viral particles but only expressed
in infected cells, this also controls for the purity of our particle
preparation. When virus particles were probed with antibodies for
ppUL83orppUL32similaramounts ofproteinsweredetected inall
Figure 2. Demonstration of the genomic rearrangement by
Southern blot analysis. Respective recombinant BAC DNAs were
digested with EcoRV and separated by agarose gel electrophoresis (A),
(D) and (G). A size marker is shown on the gel with the fragment sizes
indicated on the right side. Subsequently the gel was blotted and
subjected to southern hybridization analysis using the [
32P]dCTP
labelled gene-specific (B, E and H) detailed below or an EYFP-specific
probe (C, F and I). (A) BAC DNA of HCMV TB4-IE2-EYFP-kana
+ (lane 1),
TB4-IE2-EYFP-kana
2 (lane 2) and TB4wt (lane 3). (B) Southern analysis
using UL123 (IE2)- and UL120-specific probes. (D) BAC DNA of HCMV
TB4-UL83-EYFP-kana
+ (lane 1), TB4-UL83-EYFP-kana
2 (lane 2) and TB4wt
(lane 3). (E) Southern blot using UL83- and UL82-specific probes. (G)
BAC DNA of HCMV TB4-UL32-EYFP-kana
+ (lane 1), TB4 UL32-EYFP-kana
2
(lane 2) and TB4wt (lane 3). (H) Southern analysis using UL32- and UL31-
specific probes.
doi:10.1371/journal.pone.0009174.g002
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ppUL83-EYFP, which was supplemented by a band at 65 kDa,
possibly a product of incomplete synthesis of the fusion product as
outlined above. Finally, an additional major tegument protein,
ppUL82 (pp71), was also present in all preparations at equal
amounts. Thus, all virus variants expressed fusion proteins of the
expected size, and the ppUL83- and ppUL32-fusion proteins were
correctly incorporated into virus particles.
Kinetics of Intracellular Localization of Recombinant
Viruses Compared to the Wild-Type Virus
We then analyzed, if the intracellular localization of the viral
EYFP-fusion proteins corresponded to the situation in wild type
infected cells. For this, we infected HFF cells with wild type virus
and the three different recombinant viruses and performed
immunofluorescence analyses at different time points post
infection. For TB4-IE2-EYFP a nuclear localization was observed
at all time points (Fig. 5A). As in wild type-infected cells, IE2
showed a diffuse nuclear staining at 24 hpi, which developed into
a specific subnuclear staining of inclusion bodies later during
infection. The staining of an IE2-specific rabbit serum showed
clear overlap with EYFP fluorescence. In cells infected with TB4-
UL83-EYFP a punctate surface staining from adhered particles
was observed 6 hpi along with nuclear accumulation of ppUL83
from infecting particles (Fig. 5B, top row). For ppUL83-EYFP only
weak nuclear staining could be detected, potentially due to the fact
that only a fraction of ppUL83 in virus particles was fused to
EYFP (Fig. 4G). During the early phase a nuclear localization was
detected, whereas in the late phase the protein migrated to the
cytoplasm (Fig. 5B) as in the wild type virus infected cells. Again a
close overlap of EYFP fluorescence and staining by a monoclonal
antibody specific for ppUL83 was observed. Finally, ppUL32-
EYFP was first detected during the late phase (72 hpi) and was
localized towards the periphery of the nucleus and in the
cytoplasm throughout the late phase (Fig. 5C). Signals from EYFP
fluorescence and staining by a ppUL32 specific monoclonal
antibody showed a perfect overlap. The sequence of expression of
the fusion-proteins corresponded to their respective gene expres-
sion kinetic class, with IE2-EYFP being detected from 6 hpi,
ppUL83-EYFP from 24 hpi and ppUL32-EYFP in the late phase
at 72 hpi. For all recombinant viruses the EYFP fluorescence
signal corresponded to the signal of the respective viral fusion
partner and its localization in wild type infected cells.
Use of Recombinant Viruses for Testing Neutralizing
Antibodies
To determine, whether the infection with these viruses could be
quantified, we established the infection in the 96-well format and
measured the fluorescence signal in live cells using a Cary Eclipse
fluorescence spectrophotometer. First, we determined the best
time-point for measurement and analyzed the dependence of the
fluorescence signal on the MOI used for infection. We infected
HFF cells with different MOI ranging from 0.01 to 10 and
measured fluorescence intensity in arbitrary units. We obtained
the best results 8 dpi, which was chosen for further measurements.
As shown in Fig. 6A all viruses showed a nearly linear correlation
between fluorescence signal and the viral MOI over about two
orders of magnitude. The fluorescence signal intensities for TB4-
IE2-EYFP and TB4-UL83-EYFP were similar and 3-4-fold higher
than for TB4-UL32-EYFP.
To evaluate the use of these viruses for measuring virus
inhibitors, we first used the TB4-IE2-EYFP to measure inhibition
of virus entry by neutralizing antibodies. For these experiments we
chose to infect cells with MOI of 0.1. Virus was preincubated with
Flebogamma
R, a commercial hyperimmune globulin preparation,
a neutralizing antibody directed against glycoprotein H (14-4B)
and a non-neutralizing antibody (27–287) directed against
glycoprotein B. As demonstrated in Fig. 6B, the inhibition by
Flebogamma
R and the neutralizing antibody was readily detected.
The EC50 for Flebogamma
R was determined at a dilution of 1/
1024 and for anti-gH the EC50 was at a dilution of 1/512. These
results were also confirmed by fluorescence microscopy. As
control, after preincubation with different concentrations of the
non neutralizing anti-gB antibody no reduction in fluorescence
intensity was observed.
In additional experiments we evaluated the effect of GCV on
the replication of TB4-IE2-EYFP, TB4-UL83-EYFP and TB4-
Figure 3. Virus growth kinetics of recombinant viruses in
human foreskin fibroblasts. HFF were infected with TB4-wt (circles),
TB4-IE2-EYFP (squares), TB4-UL83-EYFP (triangles) and TB4-UL32-EYFP
(crosses) at MOI of 1 (A), 0.1 (B) and 0.01 (C). Supernatant was collected
and titrated over a range of 10 days post infection.
doi:10.1371/journal.pone.0009174.g003
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Safire 2, which allowed us to detect signals as early as 4 dpi. Using
the three viruses we established EC50 values for GCV of
5.4360.15 mM, 7.5860.39 mM and 8.0960.06 mM, respectively.
These experiments demonstrate the use of these viruses to quantify
infection and antiviral activities.
Use of Recombinant Viruses for Antiviral Screening
To demonstrate the feasibility of antiviral screening with these
viruses, we used a library of cellular kinase inhibitors. As before
infections were performed in the microplate format and measured
in the Tecan Safire 2 microplate reader at 4 dpi. Inhibitors were
added at a concentration of 10 mM at the time of infection and
replaced every second day. We first evaluated the toxicity of the
compounds in HFF used in our experiments (Fig. 7A). In several
samples cells died (samples 1, 45) or were severely compromised
(less than 50% viability; samples 4, 10, 49) indicating that the
inhibitors were added at a toxic concentration. For cells treated
with most inhibitors or different concentrations GCV the viability
was above 50%. Among the kinase inhibitors showing a cell
viability of 80–90% at the drug concentration used, we observed
with all viruses a strong inhibition (less than 25% fluorescence
intensity) for two compounds (Rottlerin and Tyrphostin 9, samples
2 and 3) (Fig. 7B). An additional compound (Ro 31–8220, sample
4) showed strong inhibition but also a severely compromised
viability (33%), while Staurosporine (sample 1) was toxic for all
cells. Thus, we could clearly show that the fluorescent viruses can
be used to identify inhibitory compounds in a high throughput
screening system.
When we compared whether the three fluorescent viruses
produced similar results we observed, that some compounds
produced differential pattern of inhibition. Two compounds (KN-
93 and Kenpaullone, samples 15 and 74) showed a more
pronounced inhibition of TB4-UL83-EYFP or TB4-UL32-EYFP
compared to TB4-IE2-EYFP with a high viability of the non-
infected cells, while others (samples 5-Iodotubercidine, GF-
109203X or BML-265, samples 10, 20 and 34) had a more
reduced cell viability (30–50%). These compounds could be
involved in the regulation of effects selective for specific phases of
the replicative cycle. The confirmation of these effects would
require additional experiments at different concentrations, which
were beyond the scope of this work.
Finally, we analyzed the nucleocytoplasmic translocation of
ppUL83-EYFP on the single cell level (Fig. 8). For this we
determined for each sample the percentage of cells showing a
cytoplasmic translocation. In samples infected with TB4-UL83-
EYFP we observed a translocation to the cytoplasm in more than
80% of the cells (Fig. 8A, sample 2). For mock infected cells
Figure 4. Western blot analysis of recombinant viruses. At 72 hpi, TB4- and recombinant virus-infected HFF (MOI of 1) were harvested, lysed
and the proteins were separated by a 10% SDS-PAGE. Detection was done by using specific antibodies against the viral fusion partner or the
fluorescent protein. (A) detection of IE1+2 with polyclonal rabbit anti-IE1+2. (B) anti-GFP antibody. (C) detection of ppUL83 and ppUL83-EYFP with
specific anti-pp65 or (D) anti-GFP antibody. ppUL32 was detected with an specific anti-ppUL32 antibody (E) or also with the anti-GFP antibody (F). In
(G) the lysates of cell free viral stocks of TB4-wt (lane 1), TB4-IE2-EYFP (lane 2), TB4-UL83-EYFP (lane 3) and TB4-UL32-EYFP (lane 4) were separated,
blotted and detected with antibodies specific for major capsid protein (MCP, pUL86), GFP, ppUL32, ppUL82 and ppUL83. The stocks had been
adjusted to equal levels of MCP.
doi:10.1371/journal.pone.0009174.g004
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no EYFP fluorescence was present. Using the nuclear export
inhibitor leptomycin B as positive control we detected a
reduction to 22% (Fig. 8B, sample 81). For most of the remaining
compounds we measured cytoplasmic translocation rates around
70–80%. For three compounds (Tyrphostin 51, GW 5074, SC-
514; samples 35, 63, 79) somewhat lower rates of 50–60% were
detected. Whether these inhibitors indeed have a direct or
indirect role in nucleocytoplasmic translocation of ppUL83 will
require more detailed investigations. Several samples were
excluded from the analysis since not enough cells could be
analyzed. In summary, we could show that all three viruses
developed are useful for fast screening of inhibitors of HCMV
infection. In addition, the TB4-UL83-EYFP virus can be used to
analyze nucleocytoplasmic translocation in a high-content
setting.
Figure 5. Immunofluorescence analysis of HFF cells infected with recombinant viruses. The co-localisation of viral protein and EYFP in HFF
infected with the recombinant virus was detected by fluorescence microscopy at 406magnification. HFF were infected with TB4-IE2-EYFP (A), TB4-
UL83-EYFP (B) or TB4-UL32-EYFP (C) with MOI 1 and fixated at 6, 24, 48 and 72 hpi as indicated on the left side. Cells were stained with mouse
monoclonal antibodies directed against IE1–2 (E13) (A), ppUL83 (B) or ppUL32 (XP-1) (C) and Alexa-Fluor555 conjugated secondary antibody. Single
channel recordings of DNA (Dapi), EYFP and the viral protein portion (red staining with Alexa-Fluor555) are shown in the left three columns; merged
images are in the rightmost column. The time after infection is indicated on the left side.
doi:10.1371/journal.pone.0009174.g005
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In this study, we constructed three different recombinant HCMV
containing fusions of EYFP to viral proteins of different gene
expression kinetic classes. We could show that all recombinant
viruses grew similar to wild-type and observed no disturbance of
protein expression and intracellular localization. In consideration of
the urgent need to find new antiviral agents for the treatment of
patients, we established a new method to measure the effect of
antivirals in intact cells rather than fixated cells or cell extracts.
To generate the recombinant viruses we developed a vector,
where EYFP was placed next to a kanamycin resistance marker, to
Figure 6. Testing measurement of antiviral agents. HFF infected in 96-well plates and fluorescence was measured in live cells by fluorescence
spectrometry or detected by live microscopy at 10-fold magnification. (A) The relationship of relative fluorescence intensity (RFI) and multiplicity of
infection is shown in the left panel for cells infected with the indicated viruses for 8 days. The panels on the right show cells infected with TB4-IE2-
EYFP (5 dpi) and TB4-UL83-EYFP or TB4-UL32-EYFP (8 dpi) at the indicated MOI. (B) Measurement of neutralizing activity using TB4-IE2-EYFP. Virus
was incubated with different dilutions of Flebogamma
R (5%) (upper row) or supernatant from hybridoma cell lines producing antibodies directed
against anti-gH (14-4B) (middle row) or anti-gB (27–39) (bottom row). HFF were infected at MOI 0.1 and relative fluorescence intensities recorded at
9 dpi are shown in the panels on the left. Corresponding microscopic images are shown in the panels on the right.
doi:10.1371/journal.pone.0009174.g006
HCMV Antiviral Test with YFP
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9174be able to select for transfer. Both genes were amplified with
primers containing sequences homologous to the desired insertion
site. The kanamycin gene was flanked by FRT-sites, which were
then used by FLP recombinase to remove the resistance marker.
As a result, EYFP was integrated into the viral genome and one
FRT site along with flanking vector sequences of a total 88 bp
remained after the marker excision. Previously we had used a
similar strategy for re-insertion of a deleted gene into a deletion
mutant of HCMV [34]. This strategy allowed the successful and
straightforward fusion of EYFP to the C-terminus of three viral
proteins.
So far only few recombinant herpesviruses encoding fluorescent
proteins have been described [16,17,23,35]. For HCMV,
recombinant viruses expressing EGFP from HCMV enhancer/
promoter were generated for different strains and used for
screening antivirals [22–24,36]. Fusion proteins have been
generated by fusing EGFP with IE2 and ppUL32 (pp150), but
only the ppUL32-fusion has been analyzed in detail [26]. In our
study we generated fusions of EYFP with three viral proteins, IE2,
ppUL83 and ppUL32. All recombinant viruses were viable and
grew to the same extent as the wild type virus. For the ppUL83-
EYFP fusion this was expected, since the deletion of UL83 did not
affect viral growth in fibroblasts. However, both IE2 [6,7] and
UL32 [13,14,37,38] are essential genes. Our observation that both
viruses with fusion of EYFP fused to IE2 or UL32 did not show
any growth defect or slowdown of the replicative cycle implies that
no essential function of these proteins is affected in HFF.
We first analyzed whether the recombinant viruses could be
used for investigations of the dynamics of virus infection. For this
the fusion proteins needed to be expressed and localized correctly.
Since EYFP is a spectral variant derived from EGFP by a few
point mutations we could use an anti-EGFP antibody to detect
Figure 7. Screening a kinase inhibitor library. A kinase inhibitor library (lanes 1–80) was used to measure cell viability (A) or inhibition of virus
replication using TB4-IE2-EYFP (B), TB4-UL83-EYFP (C) or TB4-UL32-EYFP (D). All measurements were done at 4 dpi. (A) To determine cell viability all
cells remained uninfected. Cell viability of mock infected cells was set 1.0. (B)–(D) Fluorescence intensity was measured in a Tecan Safire 2.
Background (uninfected cells) was subtracted from all samples and normalized to infected cells (100%). Inhibitors were ordered according to the
inhibition of TB4-IE2-EYFP.
doi:10.1371/journal.pone.0009174.g007
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fluorescent fusion partner in all recombinant viruses by using
either a specific antibody or an antibody directed against GFP. In
all cases a shift in protein size of about 26 kDa, the size of EYFP,
was observed. Only in the case of ppUL83 a shorter specific band
of about the size of native ppUL83 was observed. In principle,
such a form could arise by incomplete synthesis or alternatively by
post-translational processing. The latter case would generate free
EYFP, which would be detrimental to the use of the virus for
analysis of intracellular dynamics. However, the anti-EGFP
antibody did not detect any free EYFP, favouring the first
hypothesis, namely incomplete synthesis. In the next step, we
analyzed the localization of the EYFP-fusion proteins. We
compared both the intracellular localization in wild type and
recombinant virus, and the fluorescence distribution arising from
EYFP and the viral protein stained by specific antibodies. In all
cases a close overlap was observed. IE2 showed a purely nuclear
staining, as reported [4]. ppUL83 was localized to the nucleus
during the early phase of infection and moved to the cytoplasm in
the late phase [39]. At immediate-early times a punctate pattern
on the cell surface could be detected, potentially due to adhered
viral particles. ppUL83 from infecting particles accumulated in the
nucleus and could be clearly detected by antibody staining. In
contrast, EYFP-fluorescence was much weaker, which can be
explained by the fact that in particles of TB4-UL83-EYFP only
part of ppUL83 is fused to EYFP as shown by immunoblot.
Finally, during the late phase we could detect ppUL32 only in the
cytoplasm [40]. In summary, the fusion of EYFP to the viral
proteins did not affect their respective expression or localization,
which makes these recombinant viruses useful tools for the analysis
of dynamic processes during viral infection.
As application we explored the use of these recombinant viruses
to measure the potency of different antiviral agents against the
human cytomegalovirus. We could establish conditions suitable to
measure fluorescence intensity non-destructively in live cells and
could show that the relative fluorescence intensity is highly
correlated to the amount of virus (multiplicity of infection, MOI).
Previous experiments using fluorescent HCMV required lysis of
cells, which makes these measurements more labour-intensive
[22,41]. To our knowledge, this is the first demonstration of
measurement of antiviral effectiveness in intact cells using
fluorescent virus. In addition, we were able to reduce the time
until measurement from 7–8 dpi as previously described [22,41]
or initially observed (Fig. 6) to 4 dpi.
To test different antiviral substances we first infected HFF and
investigated the efficiency of ganciclovir to inhibit viral replication.
Ganciclovir (GCV) is a potent antiviral agent which is used for
treatment in patients with acute HCMV infection and disease
[42]. After treatment with GCV we found an inhibition for all
three viruses with an EC50 of 5.4–8.0 mM, which is close to the
Figure 8. High content analysis of nucleocytoplasmic shuttling of ppUL83-EYFP. Human foreskin fibroblasts were infected with TB4-UL83-
EYFP and treated with different concentrations of ganciclovir (A) or kinase inhibitors (B). Fluorescence images were recorded and analyzed in a BD
Pathway 855 for nuclear or cytoplasmic localization. (A) In the diagram on the left the ratio of cells with a cytoplasmic/nuclear staining of higher than
0.7 is shown. Infected cell were treated with 100 mM (3), 33 mM (4), 11 mM (5), 3.7 mM (6) or 1.2 mM (7) ganciclovir. Uninfected (1) or infected (2) cells
were used as controls. The localization of ppUL83-EYFP in selected samples is shown in the right panel; numbers indicate the respective sample of
diagram. (B) The diagram on the top shows the ratio of cells with a cytoplasmic/nuclear staining of higher than 0.7, as above. Kinase inhibitors (1–80)
are ordered as in Fig. 7. Leptomycin B (81) was used as positive control. The localization of ppUL83-EYFP in selected samples is shown in the lower
panels. Several samples were marked as not applicable (na), since too few cells were above an intensity threshold for EYFP fluorescence.
doi:10.1371/journal.pone.0009174.g008
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summary, using our fluorescent HCMV variants we were able to
determine correct inhibitory concentrations for GCV and ACV
using a non-destructive measurement in intact cells.
To investigate a different mode of antiviral intervention, we also
measured the capability of neutralizing antibodies to block the
infection using our marked viruses. Since neutralizing antibodies
act at the stage of virus attachment or entry we used the
recombinant virus TB4-IE2-EYFP. For neutralization we used an
approved hyperimmune serum, Flebogamma
R, as well as
supernatants from hybridoma cell lines directed against the viral
glycoproteins gH or gB, respectively. We could clearly measure a
neutralising capacity of Flebogamma
R and the monoclonal
antibody 14-4B (anti-gH) [44]. As expected, no neutralizing
activity was detected for 27–39 (anti-gB) [45]. These results
demonstrate that this fluorescent virus could also be used for
screening antiviral agents blocking entry, which have gained
attention since the licensing of Enfuvirtide as first viral entry
inhibitor for HIV treatment [46].
Finally, we performed a pilot screen using 80 kinase inhibitors.
We observed strong inhibition with two compounds (Fig. 7B,
samples 2, 3) in cells retaining almost full viability. One compound
was Tyrphostin 9, an inhibitor of PDGF receptor kinase [47],
which has recently been shown to be necessary for HCMV entry
[48]. Tyrphostin 9 had also been described to inhibit Herpes
Simplex Virus type 1 replication [49]. The other compound was
Rottlerin, which was originally described as PKC inhibitor but
might instead be directed towards other kinases [50,51]. Given
these uncertainties, it can only be noted that PKC is required for
cytomegalovirus nucleocapsid egress from the cell nucleus by
phosphorylation of lamin B [52] and Rottlerin has been shown to
block this phosphorylation in the context of Herpes Simplex Virus
Type 1 infection [53]. Additional compounds, as KN-93 and
Kenpaullone (samples 15, 74), appeared to be more effective in
reducing fluorescence from TB4-UL83-EYFP and TB4-UL32-
EYFP viruses compared to TB4-IE2-EYFP. Kenpaullone as an
inhibitor of Cyclin-dependent kinases 1 and 2 (CDK1 and 2) [54]
and glycogen synthase kinase-3b (GSK-3b) [55] could be expected
as inhibitor of HCMV replication, since it has been shown that
inhibition of CDK2 activity blocks HCMV replication and late
gene expression [56]. In our measurements the effect of
Kenpaullone on the late expressed ppUL32-EYFP appeared to
be most pronounced. This indicates that the viruses could also be
used for the discrimination of effects on different phases of viral
replication. However, an in depth analysis of the identified
compounds would require additional and more detailed experi-
ments. As additional application, we established conditions for
high content screening to detect the cytoplasmic translocation of
ppUL83-EYFP during the late phase. We could clearly discrim-
inate infected, untreated cells from infected cells treated with
Leptomycin B, which was previously reported to block the
translocation to the cytoplasm [11]. However, we could not
identify additional compounds blocking this nucleocytoplasmic
translocation among the screened kinase inhibitors. The fact that
we could identify several kinase inhibitors whose targets have been
shown to be essential for HCMV replication make it clear that
these viruses are valuable tools for antiviral screening.
When we compared the different types of fluorescent viruses, we
observed that TB4-IE2-EYFP and TB4-UL83-EYFP produced
the highest fluorescence intensity and are best used when high
sensitivity is required. Both viruses readily allowed antiviral
screening to be performed as early as 4 dpi. In an antiviral
screening setting the comparison of the three viruses will give a
first indication where in the virus life cycle an inhibiting compound
acts. We observed that some substances affected fluorescence
intensity of TB4-UL83-EYFP and TB4-UL32-EYFP to a greater
extent than that of TB4-IE2-EYFP. Since UL83-EYFP and UL32-
EYFP are expressed at a later time point than IE2-EYFP it is
plausible that these substances act during the early or late phase.
This is an improvement compared to an HCMV strain previously
used for antiviral screening [22]. Finally, the fact that UL83-EYFP
makes a nucleocytoplasmic translocation at the transition from
early to late phase it is possible to use this virus to study the
inhibition and dynamics of this process.
In conclusion, we generated and characterised successfully
recombinant human cytomegaloviruses with fusions of EYFP to
proteins of three different kinetic classes which can be used for
antiviral screening. For this task, we established conditions for the
non-destructive measurement in intact cell culture models. We
believe that these viruses will be highly useful tools to investigate
the intracellular dynamics during infection. The viruses will also be
valuable tools for time-efficient screening in intact cells and for
more advanced screening strategies, such as high content
screening [57].
Materials and Methods
Oligonucleotides
Oligonucleotides were purchased from Biomers (Ulm, Ger-
many). All oligonucleotides are noted in 59 to 39 direction.
IE2-3gfpBAC 59-TGAGCCTGGCCATCGAGGCAGCCAT-
CCAGGACCTGAGGAACAAGTCTCAGGGCCCCGGCCC-
CATGAATTCACTGATCAAGGA-39, IE2-ko5-BAC 59-CGG-
GGAATCACTATGTACAAGAGTCCATGTCTCTCTTTCC-
AGTTTTTCACCGTCGTGGAATGCCTTCGAATTC-39, ul83-
egfp-BAC 59-ACGCCTTGCCCGGGCCATGCATCGCCTC-
GACGCCCAAAAAGCACCGAGGTGGCCCCGGCCCCATG-
AATTCACTGATCAAGGA-39, UL83-ko5 59-AGTGGACGT-
GGGTTTTTATAGAGTCGTCCTAAGCGCGTGCGGCGG-
GTGGCCGTCGTGGAATGCCTTCGAATTC-39, ul32-egfp-
BAC 59-CCGTGCAGAACATCCTCCAAAAGATCGAGAAG-
ATTAAGAACACGGAGGAAGGCCCCGCGGCCATGAAT-
TCACTGATCAAGGA-39, ul32-ko5-gfp 59CACTATCCGAT-
GGTTTCATTAAAAAGTACGTCTGCGTGTGTGTTTCTT-
AACGTCGTGGAACTTCGAATTC-39
Construction of Recombinant Viruses
To generate a suitable recombination vector, we excised the
EYFP gene from pEYFP-C1 (Clontech, Heidelberg, Germany)
and cloned it into the vector pSL-FRT [58,59] using restriction
sites SalI and NheI. The resulting plasmid, pSL-FRT-Kan-EYFP,
contained the EYFP-gene adjacent to a kanamycin-resistance
gene, which was flanked by FRT-sites to allow its removal by FLP-
mediated recombination.
To generate linear fragments for recombination, we performed
touchdown PCR to amplify the whole EYFP kanamycin-cassette.
Primers included 50 nts sequence homologous to the intended
insertion site. In addition, a GPGP linker peptide was encoded by
the fusion primer between the last codon of the respective viral
gene and the first codon of EYFP to ensure conformational
uncoupling between the viral protein and the fused EYFP.
The PCR-products were purified (PCR-Purification Kit,
Qiagen, Hilden, Germany) and digested with DpnI to remove
the template plasmid. The fragments were transformed into E. coli
strain DH10B (Life Technology, Karlsruhe, Germany) containing
the bacterial artificial chromosome TB4 (short for TB40E-BAC4) and
plasmid pKD46 encoding the c, b and exo genes of the Red
recombinase system [60]. The TB4-BAC was designed to have the
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described in [61]. After selection on kanamycin, the kanamycin
resistance gene was removed by FLP-recombinase expressed from
plasmid pCP20 [62]. Removal was confirmed by colonie-PCR.
Cell Culture and Virus Reconstitution
Human foreskin fibroblasts (HFF) were cultivated in minimal
essential medium (MEM) (Gibco/BRL, Eggenstein, Germany)
supplemented with 10% fetal calf serum, 2 mM L-Glutamine
(Biochrom AG, Berlin, Germany), 100 U/ml Penicillin/100 mg/
ml Streptomycin (Gibco/BRL). The cells were grown at 37uC with
95% humidity and 5% CO2.
For reconstitution, DNA from recombinant BAC clones was
purified by alkaline lysis (Midi Prep PC100, Macherey & Nagel,
Du ¨ren, Germany) and transfected into HFF using the EasyjecT
OptimaH electroporation system (EquiBio Ltd., Middlesex, UK)
with the settings 200 V and 1500 mF. After electroporation cells
were seeded into 75 cm
2 flasks and incubated for 2 weeks to let
plaques develop. The successful reconstitution was monitored by
fluorescence microscopy. Cell-free virus stocks were produced by
ultracentrifugation of the supernatants of infected HFF.
Southern-Blot Analysis
BAC-DNA was digested with the restriction enzyme EcoRV and
separated by gel electrophoreses using a 0.6% agarose-gel. For
blotting, the gel was washed for 20 min in 0.25 M HCl, rinsed in
water followed by incubation for 30 min in 1.5 M NaCl and
shortly washed with 0.5 M NaCl. The gel was then equilibrated in
transfer buffer (1.5 M NaCl and 0.25 M NaOH) and nucleic acids
transferred to a Hybond N nylon membrane (Amersham,
Germany) by capillary blot [63]. After over night transfer the
DNA was UV-crosslinked to the membrane (CL-1000 Ultraviolet
Crosslinker UVP, Cambridge, UK).
Probes for hybridization were generated by PCR amplification
and subsequent agarose gel purification. Radioactive labelling was
performed by random hexamer priming using Ready-to-go DNA
labelling beads (Amersham Pharmacia Biotech, USA) and a
32P-
dCTP. Radioactive hybridizations were performed in a hybrid-
ization incubator (Robbins Scientific, Sunnyvale, CA) essentially
as described previously [64]. For prehybridization, filters were
incubated for at least 4 h at 42uC in a solution containing 50%
formamide, 5x SSC (1x SSC is 0.15 M NaCl plus 0,015 M sodium
citrate), 50 mM sodium phosphate pH 6.5, 5x Denhardt’s solution
and 1 mg/ml yeast RNA (Fluka, Taufkirchen, Germany).
Hybridizations were performed for at least 24 h in hybridization
solution containing 50% formamide, 5x SSC, 20 mM sodium
phosphate pH 6.5, 5x Denhardt’s solution and 500 mg/ml yeast
RNA. Filters were then washed several times with buffer
containing 20 mM sodium phosphate, 0.1% sodium dodecyl
sulfate (SDS) and decreasing concentrations of SSC. For reprobing
of the filters, the radioactive probe was removed by two
incubations in 0.1% SDS at 95uC for 30 min. Bound probes
were detected on Kodak X-Omat films.
Virus Growth Kinetics
For virus growth kinetics, 4610
4 HFF were seeded into a 24-
well plate and infected with a multiplicity of infection (MOI) of 1, 0.1
or 0.01 for TB4-wt and all three different variants. After infection
the plates were centrifuged for 30 min with 2000 rpm at room
temperature and incubated for 3 h after the centrifugation.
Thereafter, the cells were washed with PBS and the medium
was changed. At day 1, 3, 5, 7 and 10 after infection supernatants
were harvested and stored frozen in sucrose phosphate-buffer at
270uC. After the titration using HFF in 96-well plates the plaque
forming units (pfu) per ml were determined. All titrations were done
in triplicates in three independent experiments.
Immunoblot
HFF were infected with MOI of 1 for 72 hours in 6-well plates
and then harvested by scraping the cells off in 500 ml PBS. Cell
pellets were resuspended in 5xSDS-Buffer (200 mM Tris, 5 mM
EDTA, 1 M sucrose, 0.1% bromphenole blue, 1 mM DTT and
pH 8,8) and boiled at 95uC for 5 min. The cell-lysates were
separated by using a 10% SDS-PAGE and blotted on a PVDF-
Membrane. For detection rabbit serum directed against IE1+2
[65] and GFP (Gentaur, Bru ¨ssel, Belgium) or mouse monoclonal
antibodies directed against ppUL83 (28–77) [66] and ppUL32
(XP-1), [67] were used. We used goat anti-rabbit or goat anti-
mouse HRP-labelled secondary antibodies (Pierce, Ireland).
For the detection of major tegument proteins and fusion
proteins in virus particles, supernatant from infected cells was
clarified from cellular debris by low speed centrifugation
(3000 rpm, 10 min) followed by ultracentrifugation (28000 rpm,
70 min) to concentrate virus particles. Virus stocks were adjusted
for equal levels of major capsid protein by titration and
immunoblot detection. For detection, rabbit serum directed
against GFP (Gentaur, Bru ¨ssel, Belgium), ppUL32 (XP1-5) [67]
and ppUL82 (M. Winkler, unpublished data) or mouse monoclo-
nal antibodies directed against pUL86 (28-4) [68] and ppUL83
(28–77) [66] were used. We used goat anti-rabbit or goat anti-
mouse HRP-labelled secondary antibodies (Pierce, Ireland).
Immunofluorescence
For immunofluorescence analysis, 4610
4 HFF were seeded on
glass cover slips in 24-well plates and incubated overnight. Cells
were infected with MOI of 0.5 and incubated for 24, 48 and
72 hours. For fixation cells were incubated in 4% PFA for 10 min
and 0.1% Triton X-100 for 2 min followed by washing steps in
PBS. Viral proteins were detected using specific primary
monoclonal mouse antibodies against ppUL83 (Cinapool, Ar-
gene), ppUL32 (XP-1) or IE1–2 (E13, Argene). As secondary
antibody we used Alexa555-labelled polyclonal goat anti-mouse
antibody (Invitrogen).
Antiviral Screening
To assess the usefulness of the TB4-IE2-EYFP, TB4-UL83-
EYFP or TB4-UL32-EYFP virus variants for detection of antiviral
activity, we performed infection experiments in 96-well plates. We
seeded 1.7610
4 HFF per well in culture media (as described
before) and incubated at 37uC over night. To measure the relation
between multiplicity of infection and fluorescence intensity, we
measured different MOI after 8 days of incubation. For this
experiment the cells were infected with MOI of 10, 3, 1, 0.3, 0.1
and 0.01.
To test viral sensitivity for antiviral agents, cells were infected
with TB4-IE2-EYFP, TB4-UL83-EYFP or TB4-UL32-EYFP at
MOI of 0.1. Ganciclovir (GCV, Cymeven, Syntex, Germany) was
added to the infected cells using different concentrations. After 9
days of incubation at 37uC, cells were washed and incubated in
PBS for the measurement. PBS gave the best results compared to
medium without pH-indicator or normal medium. Relative
fluorescence intensity was measured using a fluorescence spectro-
photometer (Cary Eclipse, Varian, Darmstadt, Germany). Using
excitation and emission slit width of 10 nm the emission was
scanned from 500 nm to 600 nm at an extinction setting of
480 nm.
To measure neutralization by antibodies, TB4-IE-EYFP (MOI
of 0.1) was pre-incubated with Flebogamma (5%; Grifols,
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monoclonal anti-gB (27–39) [45] for 1 hour at 37uC and 15 min at
4uC. After incubation we transferred the pre-incubated virus-
antibody mix to the cells and measured the relative fluorescence
intensity again after 8 days.
For screening a compound library, we seeded 1.7610
4 HFF per
well in 96-well plates in culture media and incubated at 37uC over
night. Cells were infected with fresh supernatant of TB4-IE2-
EYFP, TB4-UL83-EYFP or TB4-UL32-EYFP. Virus supernatant
was titrated in parallel and corresponded to a MOI of 0.3 to 1. As
compounds we used a kinase inhibitor library (Enzo, Loerrach,
Germany); each inhibitor was tested in triplicates. Inhibitors were
added together with virus at a final concentration of 10 mM and
were replaced every second day. For measurements cell culture
medium was removed and cells were washed twice in PBS.
Measurements were taken in a Safire 2 (Tecan, Crailsheim,
Germany) from the top at excitation wavelength 485 nm (20 nm
bandwidth) and emission wavelength 525 nm (20 nm bandwidth)
with an integration time of 40 ms and 10 reads per well. We used
optimal gain, optimized Z-position and high sensitivity flash mode.
Background was substracted from raw data and infected cells were
normalized to 100%. Calculations and descriptive statistics were
carried out in Excel. EC50 values were determined with the IC50
package in the R environment [69]. We use the term EC50 as the
FDA recommended this term in 2007 for use in cell-based dr-
ug susceptibility testing (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm071173.
pdf). Cell viability was measured in parallel plates using the colorimetric
WST-1 cell proliferation assay (Roche, Mannheim, Germany).
The nucleocytoplasmic translocation of ppUL83-EYFP was
analyzed in a Pathway 855 (Beckton-Dickinson; Heidelberg,
Germany). Two hours before imaging live cells Hoechst 33342
(Invitrogen, Karlsruhe, Germany) was added at a final concen-
tration of 1 mg/ml to allow delineation of the nuclei. A matrix of
363 images was taken for each well (Olympus 20X objective NA
0.75, EYFP: excitation filter 500/20, emission filter 535/30). To
define regions of interest, the Hoechst stained nuclei where
segmented. To define cytoplasmic localization, a second ring-
shaped mask around a nucleus was defined starting 10 pixels away
from the nucleus and reaching 10 pixels into the cytoplasm. The
gap between the nuclear mask and the ring mask reduces nuclear
fluorescence in the cytoplasmic region. The algorithm automat-
ically prevents adjacent ring masks from overlapping. All image
processing was performed using the BD-Attovision Software
Version 1.6.1. To exclude background staining, we set a threshold
for EYFP nuclear staining at an intensity of 450. Samples with less
than 40 cells above this threshold were excluded from further
analysis (Fig. 8: na, not applicable). Since ppUL83 first
accumulates in the nucleus and moves to the cytoplasm in the
late phase, we used a ratio of cytoplasmic EYFP/nuclear EYFP of
more than 0.7 to count cells as positive for cytoplasmic
translocation. The percentage of cells positive for cytoplasmic
translocation related to the total number of cells above the
intensity threshold was used to measure the rate of translocation.
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